The Point Where More Protein Stops Helping

Keywords: All-Cause Mortality, Cardiometabolic Risk, Fibroblast Growth Factor-21 (FGF-21), Healthy Aging, Insulin-Like Growth Factor-1 (IGF-1), Longevity, Muscle Protein Synthesis, Plant-Based Diet, Protein Intake, Protein Restriction, Sarcopenia, Vitamins Minerals Supplements, mTOR

The Age of Protein Panic

Over the last decade, protein has shifted from a basic macronutrient to a cultural obsession. Supermarket aisles are filled with high‑protein bars, shakes, cereals, and even water, promoted as universally healthier options that build muscle, burn fat, and slow aging, and many patients now track grams of protein as closely as they once tracked calories. Emerging evidence, however, suggests that indiscriminately pushing protein to very high intakes, particularly from animal and ultra‑processed supplemental sources may carry metabolic and cardiovascular costs that conflict with the goal of healthy longevity. In a large UK Biobank analysis, high‑protein diets were associated with a 39% higher risk of major adverse cardiovascular events and higher all‑cause mortality compared with low‑protein diets, with risk rising especially beyond about 1.8 g/kg/day. At the same time, experimental work shows that strategic protein restriction can increase energy expenditure, elevate fibroblast growth factor‑21 (FGF‑21), and activate pathways linked to improved metabolic flexibility and lifespan, challenging the simplistic “more is always better” narrative.

The modern high‑protein message originated from appropriate concerns about sarcopenia and functional decline in older adults, in whom resistance exercise plus adequate protein clearly enhances muscle protein synthesis and helps maintain strength and independence. Over time, this rationale has been generalized to younger and metabolically diverse populations, amplified by social media and food marketing that normalize intakes of 2–3 g/kg/day even in non‑athletes, despite limited evidence that such levels confer additional benefit and growing signals of harm in large cohorts. Compounding the issue, many individuals pursue high protein primarily through ultra‑processed protein products, and independent testing has identified heavy metals such as lead and cadmium in a substantial proportion of commercial powders and shakes, sometimes exceeding conservative daily limits in a single serving. Cohort data further indicate that source matters: higher plant protein intake and substitution of plant for animal protein associate with lower cardiovascular and all‑cause mortality, whereas higher animal protein, especially from red and processed meats, links to higher risk.

Mechanistically, protein, particularly essential amino acids, activates IGF‑1 and mTORC1 signalling, supporting muscle protein synthesis and tissue repair but, when chronically overdriven, potentially accelerating aging and cancer in susceptible contexts. Protein restriction reduces IGF‑1 and growth signalling, reproducing aspects of caloric restriction biology, and FGF‑21 appears necessary for many of the metabolic and longevity benefits of low‑protein diets in animal models. Clinically, very low or cyclically lower protein intakes may be appropriate as metabolic tools for younger or middle‑aged, physically active individuals with adequate muscle mass, whereas older, sarcopenic, or multimorbid patients generally require higher protein intakes, alongside resistance training, to preserve function. Overall, current data suggest moving from generic high‑protein messaging to a precision approach: tailoring protein amount, source, and timing to age, metabolic status, and clinical goals, and avoiding reflexive promotion of very high, animal‑heavy, supplement‑driven protein intakes that may increase long‑term cardiometabolic and oncologic risk.

How We Got Here: The Rise of “More Protein is Always Better”

The modern “more protein is always better” narrative arose from genuine clinical concerns about aging and muscle loss. Age‑related sarcopenia and functional decline are strongly linked to lower quality of life, loss of independence, and increased mortality, and older adults frequently under‑consume protein relative to anabolic needs. Experimental and clinical data show that resistance exercise combined with adequate, and often higher, protein intake stimulates the IGF‑1–Akt–mTOR pathway, increases muscle protein synthesis, and helps preserve muscle mass and strength in older adults, partially overcoming age‑related anabolic resistance to both food and exercise. These findings have led expert groups and consensus statements to endorse protein intakes above the minimum recommended dietary allowance for many older individuals as a strategy to prevent frailty and functional decline [1,2,3].

Over time, this age‑specific message has been generalized well beyond its original context. Social media, fitness culture, and commercial nutrition messaging have progressively reframed high‑protein diets as universally beneficial, often implying that there is effectively no upper limit to “healthy” protein intake. Daily targets of 2–3 g/kg body weight have been popularized even in non‑athlete, metabolically diverse populations, despite a lack of robust evidence for superior outcomes at these levels and emerging data suggesting potential harm. Large prospective studies, including UK Biobank analyses and other cohort work, do not support a blanket recommendation for very high protein intake across the lifespan and indicate increased cardiovascular and all‑cause mortality risk at higher intakes, with some signals of risk appearing once protein exceeds roughly 1.8 g/kg/day [4].

In parallel, the wellness market has produced a rapid expansion of ultra‑processed protein products like powders, ready‑to‑drink shakes, and high‑protein snack bars, intensely marketed as convenient, health‑promoting options. These products commonly contain non‑nutritive sweeteners, flavouring agents, and other additives, and they are frequently positioned as interchangeable with whole‑food protein sources. Independent laboratory testing, however, has raised concerns about their safety profile. A large testing project by the Clean Label Project found that 47% of 160 commercially available protein powders exceeded at least one federal or state safety threshold for heavy metals, including lead, cadmium, arsenic, and mercury. Media and consumer reports have similarly documented protein powders and shakes, particularly some plant‑based and organic products with lead and cadmium levels that approach or surpass conservative daily limits in a single serving. Academic risk assessments have confirmed that measured heavy metal concentrations in a subset of protein supplements may pose non‑trivial lifetime health risks, depending on dose and frequency of use. This convergence of quantitative excess (very high protein targets) and qualitative concerns (contaminant burden and ultra‑processing) undermines the simplistic notion that more protein is inherently better and illustrates how a clinically grounded intervention for sarcopenia evolved into a generalized, commercially amplified high‑protein culture with unintended trade‑offs for cardiometabolic and toxicological risk [5,6,7,8,9,10].

What the Cohort Data Say: High Protein, Higher Risk?

Higher total protein intake, especially from animal sources and at levels above about 1.6–1.8 g/kg/day, is increasingly linked in cohort data to higher cardiovascular and mortality risk, whereas plant‑forward protein patterns generally show neutral or protective associations, with important age‑dependent nuances [4,11,12,13].

High Protein Intake and MACE Risk

A recent UK Biobank analysis of 19,420 adults followed for a mean of 13.2 years found that high‑protein diets were associated with a significantly higher incidence of major adverse cardiovascular events (MACE) compared with low‑protein diets after full adjustment for confounders. In the fully adjusted model, high protein intake was linked to higher risk of the composite MACE endpoint, heart failure, myocardial infarction, cardiovascular death, and all‑cause mortality, with risk rising particularly once daily intake exceeded roughly 1.8 g/kg body weight. Age modified this association: individuals over 55 years showed a more pronounced increase in MACE risk with high protein intake, whereas younger participants did not exhibit a clear association [4].

Protein Source: Plant versus Animal

Large prospective cohorts and pooled analyses consistently report that higher plant protein intake, and statistical substitution of animal protein with plant protein, associate with lower all‑cause and cardiovascular mortality and lower type 2 diabetes incidence. In contrast, higher intake of animal protein, especially from red and processed meats, which tend to co‑deliver saturated fat, heme iron, sodium, and advanced glycation end‑products is repeatedly linked with higher coronary heart disease and cardiovascular mortality risk. These source‑specific findings align with broader dietary pattern data showing that legume‑, nut‑, soy‑, and whole‑grain‑rich, plant‑forward diets are associated with more favourable cardiometabolic outcomes than patterns dominated by red and processed meats [11,12,14,15].

Aspect	Higher Plant Protein	Higher Aniaml (red/processed) protein
All-cause mortality	Lower risk when substituted for animal protein [11,12,14]	Higher risk in multiple cohorts [11,12]
Cardiovascular mortality	Lower CVD mortality with plant-for-animal substitution [11,12,14]	Higher CHD/CVD mortality, especially with red/processed [11,12,14]
Dementia mortality (older women)	Lower dementia-related mortality with more plant protein [12,15]	Higher dementia-related mortality when plant protein is low [12,15].
Type 2 diabetes incidence	Lower T2D risk when replacing animal with plant protein [11]	Higher T2D risk with higher red/processed meat protein [11]

Table 1. Protein Source and Cardiometabolic Outcomes

Age, IGF-1, and Protein “Sweet Spots”

A seminal analysis of U.S. adults showed that among participants aged 50–65 years, high protein intake (particularly from animal sources) was associated with markedly higher overall mortality and a roughly four‑fold increase in cancer mortality over 18 years of follow‑up, in parallel with higher circulating IGF‑1 levels. In this midlife group, each 10 ng/mL increase in IGF‑1 further amplified cancer mortality risk among those consuming high protein, supporting a mechanistic link between protein‑driven IGF‑1 signalling and oncogenesis. Interestingly, in adults aged 66 years and older, higher protein intake, especially when IGF‑1 levels were not elevated was associated with lower cardiovascular mortality and better survival, likely reflecting the importance of protein for maintaining muscle mass, function, and resilience in later life [13].

Clinical Implications and Context

Taken together, these cohort and mechanistic data argue against a uniform high‑protein target across the life course and across protein sources. For younger and midlife adults (roughly ≤65 years), keeping total protein in a moderate range, prioritizing plant‑dominant sources, and avoiding chronic intakes far above about 1.6–1.8 g/kg/day may help balance muscle maintenance with long‑term cardiometabolic and cancer risk. In older adults, higher protein intake, ideally from plant and fish/poultry sources within overall healthy dietary patterns appears beneficial for preserving lean mass, functional status, and survival, although the optimal individualized range remains to be clarified by intervention trials [4,11,12,13,17].

Mechanisms: IGF-1, mTOR, and the Longevity Paradox

Protein, particularly essential amino acids, is a key regulator of anabolic signalling pathways such as insulin‑like growth factor‑1 (IGF‑1) and mechanistic target of rapamycin complex 1 (mTORC1), which together govern muscle protein synthesis, cellular growth, and proliferation. In skeletal muscle, resistance exercise and protein feeding acutely activate the IGF‑1–Akt–mTOR axis, leading to increased myofibrillar protein synthesis and structural remodelling that help maintain lean mass and functional capacity across adulthood. Human and animal data indicate that IGF‑1 signalling has a long‑term positive impact on muscle mass and strength, and that protein‑ and exercise‑induced activation of mTORC1 is central to the beneficial hypertrophic response that counters sarcopenia and age‑related muscle atrophy. This represents the “upside” of protein for healthy aging: less sarcopenia, fewer falls, and better preservation of physical independence [2,18,19].

The longevity paradox arises because chronic overactivation of the same growth pathways is implicated in accelerated aging, carcinogenesis, and reduced lifespan in multiple model organisms. Experimental protein restriction lowers circulating IGF‑1 and attenuates growth hormone/IGF‑1 axis activity, recapitulating several features of caloric restriction–induced longevity without necessarily reducing total energy intake. In mice and humans with genetically reduced growth hormone receptor/IGF‑1 signalling, there is a marked reduction in age‑related diseases and extended lifespan, whereas high protein intake that maintains elevated IGF‑1 is associated with higher cancer and overall mortality in middle‑aged adults, with the risk attenuating or reversing after age 65. A recent line of work reported that high protein intake causes gene‑length‑dependent transcriptional decline, shortening lifespan and accelerating aging in progeroid DNA‑repair‑deficient models, by disproportionately impairing expression of long genes involved in genome maintenance and stress resistance; notable components of this effect appear at least partly independent of canonical mTOR signalling [20,21].

Taken together, these findings suggest that protein’s impact on longevity is highly context dependent. In physically active individuals, especially older adults, adequate to moderately high protein intake that transiently stimulates IGF‑1–mTOR signalling is beneficial for maintaining muscle mass and function, and thus for disability‑free survival. By contrast, in environments characterized by caloric surplus, low physical activity, and high oncogenic exposure, chronically high protein intake that persistently elevates IGF‑1 and related growth pathways may increase long‑term cancer and cardiovascular risk and accelerate biological aging. This duality implies that the protein intake required to maximize muscle hypertrophy is not necessarily the same as the intake that optimizes lifespan and health span, and that an age‑ and context‑specific “window” of protein exposure, potentially including periods of relative protein restriction may be most compatible with both functional preservation and longevity [2,18,19,20,21].

Protein Restriction, FGF-21, and Metabolic Flexibility

When Protein Obsession Harms Real Patients

In clinical practice, “protein obsession” increasingly presents in ways that can undermine both metabolic health and psychological wellbeing. A prominent pattern is heavy reliance on ultra‑processed protein products like powders, bars, and ready‑to‑drink shakes that displace whole foods while adding non‑nutritive sweeteners, flavourings, and other additives. Independent and consumer‑driven testing initiatives, including recent Clean Label Project and Consumer Reports–inspired investigations, have documented detectable levels of heavy metals such as lead, cadmium, arsenic, and mercury in a substantial proportion of commercial protein supplements, with many products exceeding conservative daily “concerning” thresholds for lead in a single serving. Plant‑based powders, particularly pea‑based formulations, appear to be the most problematic, with some analyses noting roughly nine‑fold higher lead levels compared with dairy‑based products and approximately double the levels seen in beef‑based powders, a pattern likely related to crop bioaccumulation and processing factors. This contaminant burden means that patients who consume multiple scoops daily in pursuit of high protein targets may unintentionally increase lifetime exposure to toxic metals, with uncertain long‑term consequences [26,27,28,29].

A second pattern involves overemphasis on protein at the expense of dietary fiber, phytonutrients, and unsaturated fats, resulting in diets high in animal protein and low in plant diversity. Such patterns are associated with gut dysbiosis, increased production of atherogenic metabolites such as trimethylamine‑N‑oxide, and systemic inflammation, all of which can elevate cardiometabolic risk. Observational and experimental work indicates that diets rich in red and processed meats but poor in fiber and plant foods are linked to less favourable microbiome profiles and higher incidence of obesity, type 2 diabetes, and atherosclerotic disease. On the psychological side, a strong focus on achieving aggressive daily protein targets can foster rigid eating behaviours, guilt, and an overly mechanistic relationship with food; patients may override internal cues such as satiety, digestive discomfort, or sleep disruption in order to “hit their macros,” and macro‑tracking framed as “health optimization” may mask or perpetuate disordered eating in vulnerable individuals [26,27,28,29].

A third clinically relevant scenario is the application of very high protein diets in people with underlying kidney vulnerability, including those with diabetic nephropathy, pre‑existing hyperfiltration, or uncontrolled hypertension, often without thorough assessment of renal function or careful long‑term monitoring. While high‑protein diets do not appear to harm kidney function in people with normal renal physiology in short‑ to medium‑term trials, cohort data suggest that, in individuals with renal hyperfiltration or early chronic kidney disease, sustained high protein intake is associated with a faster rate of decline in estimated glomerular filtration rate. One community‑based prospective study reported that participants with high‑protein diets and hyperfiltration exhibited a significantly more rapid decline in renal function than those with lower protein intake, supporting the idea that high protein loads plus impaired renal reserve can accelerate progression in susceptible patients. Taken together, these patterns illustrate how a culturally reinforced drive toward ever‑higher protein intake especially via ultra‑processed supplements and animal‑heavy, low‑fiber diets can create unintended metabolic, toxicological, psychological, and renal trade‑offs, underscoring the need for individualized, risk‑aware protein recommendations in clinical practice [26,29].

Towards a More Nuanced Protein Prescription

Taken together, current evidence supports a shift away from uniform high‑protein recommendations toward individualized, context‑specific protein prescriptions that account for age, metabolic milieu, protein quality, and temporal patterning. Age is a central determinant: midlife adults (for example, under 65 years) with adequate muscle mass and higher oncogenic exposure may be best served by protein intakes that are sufficient but not excessive, potentially incorporating periodic lower‑protein days or phases to modulate IGF‑1 and growth signalling. In contrast, older adults exhibit well‑documented anabolic resistance, requiring higher per‑meal and total daily protein often in the range of at least 1.0–1.2 g/kg/day and sometimes higher, combined with resistance exercise to maximally stimulate muscle protein synthesis and preserve strength and function [1,23,30,31,32,33].

Metabolic context also shapes optimal protein strategy. Individuals with obesity, insulin resistance, or early metabolic syndrome can benefit in the short term from relatively higher‑protein, lower‑refined‑carbohydrate diets to support appetite regulation and weight loss, but longer‑term maintenance likely requires a rebalancing toward more plant‑based protein sources and moderation of total protein intake to avoid chronic overactivation of growth pathways and to improve cardiometabolic risk profiles. Protein quality is another key domain: prioritizing minimally processed plant proteins (legumes, soy, nuts, seeds), fish, eggs, and fermented dairy while minimizing processed meats and ultra‑processed protein products is consistently associated with lower all‑cause and cardiovascular mortality and better cardiometabolic outcomes. Finally, temporal patterning, such as integrating intermittent or cyclical protein restriction within an otherwise adequate‑protein diet offers a promising strategy to preserve muscle while periodically engaging FGF‑21–mediated and other stress‑response pathways linked to improved metabolic health and extended lifespan, as demonstrated in experimental models of continuous and intermittent protein restriction [11,23,32,33,34,35,36,37]

From Obsession to Precision

Protein is indispensable, yet the cultural pendulum has clearly swung from neglect to overcorrection. Current evidence indicates that indiscriminate promotion of very high protein intake, particularly from animal sources and ultra‑processed supplements may increase cardiovascular and all‑cause mortality risk and over activate growth pathways linked to aging and cancer, especially in midlife. At the same time, observational and experimental data consistently show that targeted protein sufficiency, combined with resistance training, is essential for preserving muscle mass, preventing frailty, and maintaining functional independence in older adults.

For preventive metabolic medicine and longevity practice, the goal is therefore not universal high‑protein prescription but precision: the right dose of protein, from the right sources, at the right life stage, in the right metabolic context. As clinicians and health technologists, we can help patients move beyond macro‑tracking dogma toward strategies that integrate muscle health, cardiometabolic risk, contaminant exposure, and longevity biology, transforming protein from an object of obsession into a tailored, evidence‑based tool for long‑term health rather than a one‑dimensional metric to maximize.

Reference

Pérez-Castillo ÍM, Rueda R, Pereira SL, Bouzamondo H, López-Chicharro J, Segura-Ortiz F, et al. Age-Related Anabolic Resistance: Nutritional and Exercise Strategies, and Potential Relevance to Life-Long Exercisers. Nutrients [Internet]. 2025 Nov 9;17(22):3503. Available from: https://www.mdpi.com/2072-6643/17/22/3503
Barclay RD, Burd NA, Tyler C, Tillin NA, Mackenzie RW. The Role of the IGF-1 Signaling Cascade in Muscle Protein Synthesis and Anabolic Resistance in Aging Skeletal Muscle. Frontiers in Nutrition. 2019 Sep 10;6.
Endo Y, Nourmahnad A, Sinha I. Optimizing Skeletal Muscle Anabolic Response to Resistance Training in Aging. Frontiers in Physiology. 2020 Jul 23;11.
Huang C, Yu Y, Liang W, Li J, Wang Y, Wei F, et al. Associations between High Protein Intake and Cardiovascular Diseases by Age Groups: A Cohort Study. The Journal of nutrition, health and aging [Internet]. 2026 Jan;30(1):100727. Available from: https://www.eatingwell.com/high-protein-diet-cardiac-risk-study-11854137?utm_source=chatgpt.com
High levels of lead and cadmium in protein powder, US study finds [Internet]. Ingredientsnetwork.com. 2025. Available from: https://www.ingredientsnetwork.com/high-levels-of-lead-and-cadmium-in-protein-powder-news126351.html
Irshad M, Ahmed M, Ramzan M, Fatima M, Aftab F, Mudassar Sanaullah, et al. Appraisal of potentially toxic metals contamination in protein supplements for muscle growth: A chemometric approach and associated human health risks. Journal of Trace Elements in Medicine and Biology. 2024 Sep 1;85:127481–1.
2024-25 Protein Powder Category Report CLP Insights [Internet]. Available from: https://cleanlabelproject.org/wp-content/uploads/CleanLabelProject_ProteinStudyWhitepaper_010625.pdf
LaMotte S. Lead and cadmium found in muscle-building protein powders, report says [Internet]. CNN. 2025. Available from: https://edition.cnn.com/2025/01/09/health/protein-powder-heavy-metals-wellness
Bandara SB, Towle KM, Monnot AD. A human health risk assessment of heavy metal ingestion among consumers of protein powder supplements. Toxicology Reports. 2020;7:1255–62.
Graves T. Protein Powders and Shakes Contain High Amounts of Lead, New Report Says – A Pharmacologist Explains the Data – UConn Today [Internet]. UConn Today. 2025. Available from: https://today.uconn.edu/2025/10/protein-powders-and-shakes-contain-high-amounts-of-lead-new-report-says-a-pharmacologist-explains-the-data/
Lamberg-Allardt C, Bärebring L, Arnesen EK, Nwaru BI, Thorisdottir B, Ramel A, et al. Animal versus plant-based protein and risk of cardiovascular disease and type 2 diabetes: a systematic review of randomized controlled trials and prospective cohort studies. Food & Nutrition Research [Internet]. 2023 Mar 28; Available from: https://foodandnutritionresearch.net/index.php/fnr/article/view/9003/15478
Study links plant protein intake to lower risk of deaths from cardiovascular disease, dementia – University of Iowa College of Public Health [Internet]. Uiowa.edu. 2021 [cited 2026 Mar 27]. Available from: https://www.public-health.uiowa.edu/news-items/study-shows-older-women-who-ate-more-plant-protein-had-lower-risk-of-cardiovascular-disease-death-and-dementia-related-death/
Levine Morgan E, Suarez Jorge A, Brandhorst S, Balasubramanian P, Cheng CW, Madia F, et al. Low Protein Intake Is Associated with a Major Reduction in IGF-1, Cancer, and Overall Mortality in the 65 and Younger but Not Older Population. Cell Metabolism. 2014 Mar;19(3):407–17.
Sun Y, Liu B, Snetselaar L, Wallace R, Shadyab A, Kroenke C, et al. Association of Major Dietary Protein Sources with All-cause and Cause-specific Mortality: The Women’s Health Initiative (FS03-08-19). Current Developments in Nutrition. 2019 Jun 1;3(Supplement_1).
Eating more plant protein, less red meat may lower women’s risk of early death [Internet]. www.heart.org. Available from: https://www.heart.org/en/news/2021/02/24/eating-more-plant-protein-less-red-meat-may-lower-womens-risk-of-early-death
Tong TYN, Bradbury KE, Key TJ. RE: “ASSOCIATIONS OF DIETARY PROTEIN INTAKE WITH FAT-FREE MASS AND GRIP STRENGTH: A CROSS-SECTIONAL STUDY IN 146,816 UK BIOBANK PARTICIPANTS.” American Journal of Epidemiology. 2019 Feb 12;188(5):977–8.
Jain M, Celis-Morales C, Ozanne SE, Burden S, Gray SR, Morrison DJ. Protein Source, Dietary Fibre Intake, and Inflammation in Older Adults: A UK Biobank Study. Nutrients [Internet]. 2025 Apr 26;17(9):1454. Available from: https://www.eatingwell.com/foods-lower-chronic-inflammation-study-11725947
Hajj-Boutros G, Karelis AD, Cefis M, Morais J, Casgrain J, Gilles Gouspillou, et al. Potential mechanisms involved in regulating muscle protein turnover after acute exercise: A brief review. Frontiers in Physiology [Internet]. 2023 Jan 9;13. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870712/
Clemmons DR. Role of IGF-I in skeletal muscle mass maintenance. Trends in Endocrinology & Metabolism. 2009 Sep;20(7):349–56.
Low Protein Intake Is Associated with a Major Reduction in IGF-1, Cancer, and Overall Mortality [Internet]. Bend Osteopathic Care, PC . 2014 [cited 2026 Mar 27]. Available from: https://drkyle.com/2014/03/11/low-protein-intake-and-igf-1/
Galen I van, Birkisdóttir MB, Ozinga RA, Brandt RMC, Sander Barnhoorn, Imholz S, et al. High protein intake causes gene-length-dependent transcriptional decline, shortens lifespan and accelerates ageing in progeroid DNA repair-deficient mice. npj Metabolic Health and Disease [Internet]. 2025 May 22 [cited 2025 Jun 11];3(1). Available from: https://www.nature.com/articles/s44324-025-00064-3#Sec9
Nicolaisen TS, Lyster AE, Sjøberg KA, Haas DT, Voldstedlund CT, Anne-Marie Lundsgaard, et al. Dietary protein restriction elevates FGF21 levels and energy requirements to maintain body weight in lean men. Nature Metabolism [Internet]. 2025 Mar 6; Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11946896/
Hill CM, Albarado DC, Coco LG, Spann RA, Khan MS, Qualls-Creekmore E, et al. FGF21 is required for protein restriction to extend lifespan and improve metabolic health in male mice. Nature Communications [Internet]. 2022 Apr 7;13(1). Available from: https://www.nature.com/articles/s41467-022-29499-8?utm_source=chatgpt.com
PhD CF, Zhang JP, PhD JE. Heavy Metal Contamination of Powdered Protein and Botanical Shake Mixes. Journal of Environmental Health [Internet]. 2017;80(4):8–14. Available from: https://www.proquest.com/docview/1957106515?sourcetype=Scholarly Journals
Bernstein AM, Sun Q, Hu FB, Stampfer MJ, Manson JE, Willett WC. Major dietary protein sources and risk of coronary heart disease in women. Circulation [Internet]. 2010;122(9):876–83. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20713902
“What happens in the gut, does not stay in the gut”: Why fibre, protein intake affects cardiometabolic health [Internet]. NutraIngredients.com. 2023 [cited 2026 Mar 27]. Available from: https://www.nutraingredients.com/Article/2023/11/09/Studies-show-effects-of-fibre-and-protein-intake-on-cardiometabolic-health/
Norwitz N. Two Protein Bombshells That Lower the Bar [Internet]. Substack.com. 2026 [cited 2026 Mar 27]. Available from: https://staycuriousmetabolism.substack.com/p/two-protein-bombshells-that-lower/comments
Lee J, Lee C, Ju Young Eor, Mi Kyung Kwak, Chul Sung Huh, Kim YH. Effect of consumption of animal products on the gut microbiome composition and gut health. Food Science of Animal Resources [Internet]. 2023 Sep 1;43(5):723–50. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493557/
Prioritizing Health | Microbiome of Steel: Build a Cardioprotective Gut With Fiber – American College of Cardiology [Internet]. American College of Cardiology. 2025. Available from: https://www.acc.org/Latest-in-Cardiology/Articles/2025/11/01/01/Prioritizing-Health-Microbiome-of-Steel
Deane CS, Cox J, Atherton PJ. Critical variables regulating age-related anabolic responses to protein nutrition in skeletal muscle. Frontiers in Nutrition. 2024 Aug 6;11
Deutz NEP, Bauer JM, Barazzoni R, Biolo G, Boirie Y, Bosy-Westphal A, et al. Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group. Clinical Nutrition [Internet]. 2014 Dec;33(6):929–36. Available from: https://www.espen.org/files/PIIS0261561414001113.pdf
Haghighatdoost F, Mohammadifard N, Zakeri P, Najafian J, Sadeghi M, Roohafza H, et al. Differences in all-cause mortality risk associated with animal and plant dietary protein sources consumption. Scientific Reports. 2023 Feb 28;13(1).
Rouskas K, Bocher O, Simistiras A, Emmanouil C, Mantas P, Skoulakis A, et al. Periodic dietary restriction of animal products induces metabolic reprogramming in humans with effects on cardiometabolic health. npj Metabolic Health and Disease [Internet]. 2025 Apr 9;3(1). Available from: https://www.nature.com/articles/s44324-025-00057-2
Wall BT, Cermak NM, van Loon LJC. Dietary Protein Considerations to Support Active Aging. Sports Medicine. 2014 Oct 30;44(S2):185–94.
Mariotti F. Animal and Plant Protein Sources and Cardiometabolic Health. Advances in Nutrition. 2019 Nov 1;10(Supplement_4):S351–66.
Naghshi S, Sadeghi O, Willett WC, Esmaillzadeh A. Dietary intake of total, animal, and plant proteins and risk of all cause, cardiovascular, and cancer mortality: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ. 2020 Jul 22;370:m2412.
Laeger T, Henagan TM, Albarado DC, Redman LM, Bray GA, Noland RC, et al. FGF21 is an endocrine signal of protein restriction. Journal of Clinical Investigation. 2014 Aug 18;124(9):3913–22.